777 jili games
INDIANAPOLIS (WISH) — The Indianapolis city government plans to expand its Clinician-Led Community Response program to the Indianapolis Metropolitan Police Department’s north district . City leaders said Monday that they expanded the program to 24-7 in IMPD’s downtown and east districts earlier this year. The program will expand its operations to the north district in early 2025. Licensed behavioral health professionals operate the program to provide short-term and non-police assistance to people in crisis. Leaders say it keeps police from responding to mental health emergencies. Ron Gibson, a Democrat on the Indianapolis-Marion County City-County Council , said Monday, “I know firsthand how important programs like this are. I’ve experience family members in a behavioral health crisis, and they can be traumatic for all involved. But when you have an experienced professional show up, it makes all the difference in the world.” Leaders had a news conference to announced the expansion on Monday morning at Raphael Health Center, 401 E. 34th St. According to a news release in advance, participants in the news conference included Mayor Joe Hogsett; Alexis Weaver, assistant director of social determinants of health with Office of Public Health and Safety ; Andrea Brown, director of Stepping Stones Therapy Center ; and Niki Wattson, street outreach manager and Professional Blended Street Outreach coordinator for Horizon House . This story was created from a script aired on WISH-TV.
VW workers threaten more strikes unless leadership makes better compromises
In a kindness crossover the world needs, one kid doing amazing work in Greater Victoria discovered another and is doubling down in support of a clinical trials hub for kids in B.C. Felix Townsin has a remarkably long history of philanthropy for a 14-year-old. His little sister Lexi died in 2019, just shy of her seventh birthday, of complications related to the rare genetic disorder Blau Syndrome. He was 9. When he was five, Felix wrote the book Don't Floss Your Toes, as a fundraiser for Blau syndrome (early onset sarcoidosis) and juvenile arthritis endeavours. The last of years, the Esquimalt teen has spread kindness in Lexi’s honour, most recently with the A Million Acts of Love campaign that inspired 1,016,012 acts of love worldwide by Dec. 16, 2024, which would have been Lexi’s 12th birthday. Simon Hoskins, 8, and his family – including twin sister Isabel and older brother Spencer – embarked on a similar venture, raising funds and awareness of mucopolysaccharidosis (MPS) Type IV, or Morquio. The Oak Bay boy lives with the rare progressive genetic disease. Just ahead of the holidays, Felix heard about Simon and his latest missing to fund the Clinical Trials Super Hub at BC Children’s Hospital, according to A Million Acts of Love social media post. “Inspired to help, Felix asked if Lexi’s A Million Acts of Love Tree could support Simon’s incredible project,” the post reads. “Now, every donation to Lexi’s tree helps kids like Simon access life-saving clinical trials – bringing hope to families like ours. This new hub for clinical trials will bring hope to so many.” A Million Acts of Love tree is in the Top 10 of nearly 100 fundraising trees gracing the Bay Centre in Victoria to support BC Children’s Hospital. Since the Bay Centre started hosting the annual display in 2015, it has generated over $1.4 million in critical funds for the most urgent needs at BCCH. The goal this year is to raise $100,000 and hit that $1.5 million mark. The festival runs until Jan. 5, 2025. Visit curemps.ca and lexislegacy.com to learn more about both Greater Victoria families’ ongoing efforts.Ruud van Nistelrooy enjoyed a dream start to his reign as Leicester manager after a 3-1 win over West Ham, whose boss Julen Lopetugui is under increasing pressure. Van Nistelrooy has replaced Steve Cooper at the King Power Stadium and saw Jamie Vardy open the scoring after just 98 seconds. Bilal El Khannouss and Patson Daka added goals after the break to ensure the Dutchman started with three points in style. Starting with a win! 🤩 Delivered by @bcgame #LEIWHU pic.twitter.com/X90nFSbMLm — Leicester City (@LCFC) December 3, 2024 His task is to keep the Foxes in the Premier League this season and after ending a five-game winless run they moved up to 15th, four points clear of the relegation zone. West Ham’s hierarchy will have seen what impact a managerial change can have as the jury remains out on Lopetegui, with away fans making their feelings clear by chanting “You’re getting sacked in the morning”. Niclas Fullkrug scored a consolation goal at the death but it counted for nothing and forthcoming games against Wolves, Bournemouth, Brighton and Southampton could determine the Spaniard’s future. When Van Nistelrooy went to bed last night, even he would not have dreamt of his side starting as well as they did as they went ahead with less than two minutes on the clock. One of the Dutchman’s first conversations following his appointment was to take Vardy to task for breaking his record for scoring in the most consecutive Premier League games nine years ago. And the veteran striker rolled back to the years as, living on the shoulder of the West Ham defence, he raced clear from El Khannouss’ through-ball and slotted into the corner. The linesman’s flag immediately went up but a lengthy VAR review ruled Vardy had timed his run perfectly and the goal stood. Vardy could have added a second from a similar move but this time Lukasz Fabianski denied him. The Dutchman quickly learned about the frailties of his side as West Ham created a raft of chances in search of an equaliser. Jarrod Bowen forced Mads Hermansen into a stretching save when he cut in from the right before Ings’ header crashed into the post and Max Kilman slipped at the crucial point from the rebound. Bowen, a constant threat, sent a ball across face of goal which evaded everyone before the England international was denied by a reflex save from the busy Hermansen. The Danish goalkeeper needed to be alert to tip over Mohammed Kudus’ deflected effort early in the second half before he was saved by the referee’s whistle after after his attempted punch went into his own goal, Tomas Soucek the man penalised. Leicester remained a threat on the counter-attack and that is how they doubled their lead just after the hour. Kasey McAteer was set clear down the left and his ball inside was perfect for El Khannouss to find the bottom corner from 15 yards. It was almost three as Fabianski produced an acrobatic save from Wilfred Ndidi’s header before Leicester needed a heroic piece of defending to keep their 2-0 lead intact. Crysencio Summerville bundled the ball goalwards and it was heading over the line until Conor Coady adjusted his feet and poked it clear. The Foxes, who also had a goal from substitute Bobby De Cordova-Reid chalked off by VAR, wrapped things up in the 90th minute when Daka broke clear and emphatically converted into the roof of the net. West Ham did get on the scoresheet when Fullkrug headed a corner home, but the game was already done.
Salesforce Inc earnings missed by $0.03, revenue topped estimatesBy FARNOUSH AMIRI, Associated Press WASHINGTON (AP) — Former Rep. Matt Gaetz said Friday that he will not be returning to Congress after withdrawing his name from consideration to be attorney general under President-elect Donald Trump amid growing allegations of sexual misconduct. “I’m still going to be in the fight, but it’s going to be from a new perch. I do not intend to join the 119th Congress,” Gaetz told conservative commentator Charlie Kirk, adding that he has “some other goals in life that I’m eager to pursue with my wife and my family.” Related Articles The announcement comes a day after Gaetz, a Florida Republican, stepped aside from the Cabinet nomination process amid growing fallout from federal and House Ethics investigations that cast doubt on his ability to be confirmed as the nation’s chief federal law enforcement officer. The 42-year-old has vehemently denied the allegations against him. Gaetz’s nomination as attorney general had stunned many career lawyers inside the Justice Department, but reflected Trump’s desire to place a loyalist in a department he has marked for retribution following the criminal cases against him. Hours after Gaetz withdrew, Trump nominated Pam Bondi, the former Florida attorney general, who would come to the job with years of legal work under her belt and that other trait Trump prizes above all: loyalty. It’s unclear what’s next for Gaetz, who is no longer a member of the House. He surprised colleagues by resigning from Congress the same day that Trump nominated him for attorney general. Some speculated he could still be sworn into office for another two-year term on Jan. 3, given that he had just won reelection earlier this month. But Gaetz, who has been in state and national politics for 14 years, said he’s done with Congress. “I think that eight years is probably enough time in the United States Congress,” he said.
Franklin Resources Inc. boosted its holdings in shares of Cinemark Holdings, Inc. ( NYSE:CNK – Free Report ) by 6.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,757 shares of the company’s stock after purchasing an additional 3,632 shares during the quarter. Franklin Resources Inc.’s holdings in Cinemark were worth $1,651,000 as of its most recent SEC filing. A number of other hedge funds also recently bought and sold shares of the business. Arizona State Retirement System raised its stake in Cinemark by 1.8% during the second quarter. Arizona State Retirement System now owns 30,636 shares of the company’s stock valued at $662,000 after purchasing an additional 556 shares in the last quarter. Natixis Advisors LLC raised its stake in shares of Cinemark by 2.9% in the third quarter. Natixis Advisors LLC now owns 20,638 shares of the company’s stock valued at $575,000 after acquiring an additional 583 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Cinemark by 38.7% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,145 shares of the company’s stock valued at $68,000 after acquiring an additional 877 shares during the period. GAMMA Investing LLC raised its stake in shares of Cinemark by 106.1% in the third quarter. GAMMA Investing LLC now owns 2,020 shares of the company’s stock valued at $56,000 after acquiring an additional 1,040 shares during the period. Finally, Quarry LP raised its stake in shares of Cinemark by 714.8% in the third quarter. Quarry LP now owns 1,491 shares of the company’s stock valued at $42,000 after acquiring an additional 1,308 shares during the period. Insiders Place Their Bets In other news, insider Valmir Fernandes sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $32.68, for a total value of $817,000.00. Following the sale, the insider now directly owns 179,729 shares in the company, valued at approximately $5,873,543.72. This trade represents a 12.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . 2.30% of the stock is owned by company insiders. Wall Street Analysts Forecast Growth Get Our Latest Research Report on Cinemark Cinemark Stock Up 1.3 % Shares of Cinemark stock opened at $30.95 on Friday. The company has a debt-to-equity ratio of 3.46, a current ratio of 0.98 and a quick ratio of 0.96. Cinemark Holdings, Inc. has a 1 year low of $13.19 and a 1 year high of $36.28. The firm’s 50-day moving average is $31.80 and its two-hundred day moving average is $27.31. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 1.66 and a beta of 2.38. Cinemark ( NYSE:CNK – Get Free Report ) last issued its earnings results on Thursday, October 31st. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.61. Cinemark had a net margin of 8.36% and a return on equity of 60.21%. The company had revenue of $921.80 million for the quarter, compared to analysts’ expectations of $894.90 million. During the same period in the prior year, the business earned $0.61 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, research analysts expect that Cinemark Holdings, Inc. will post 2 earnings per share for the current fiscal year. About Cinemark ( Free Report ) Cinemark Holdings, Inc, together with its subsidiaries, engages in the motion picture exhibition business. As of February 16, 2024, it operated 501 theatres with 5,719 screens in 42 states and 13 countries in South and Central America. Cinemark Holdings, Inc was founded in 1984 and is headquartered in Plano, Texas. Recommended Stories Want to see what other hedge funds are holding CNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cinemark Holdings, Inc. ( NYSE:CNK – Free Report ). Receive News & Ratings for Cinemark Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cinemark and related companies with MarketBeat.com's FREE daily email newsletter .FREMONT, Calif. , Dec. 2, 2024 /PRNewswire/ -- Lam Research Corp. (Nasdaq: LRCX). Today, the U.S. government announced additional measures to further restrict semiconductor technology exports to China . Our initial assessment is that the effect of the announced measures on Lam's business will be broadly consistent with our prior expectations. As a result, at this time we have no plans to update Lam's financial guidance for the December 2024 quarter as stated in our earnings press release on October 23, 2024 . About Lam Research Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's equipment and services allow customers to build smaller and better performing devices. In fact, today, nearly every advanced chip is built with Lam technology. We combine superior systems engineering, technology leadership, and a strong values-based culture, with an unwavering commitment to our customers. Lam Research (Nasdaq: LRCX) is a FORTUNE 500® company headquartered in Fremont, Calif. , with operations around the globe. Learn more at www.lamresearch.com . (LRCX) Caution Regarding Forward-Looking Statements: Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to but are not limited to the effect of U.S. government restrictions on semiconductor technology exports to China , the effect of such measures on Lam's business, and our outlook and guidance for future financial results. Some factors that may affect these forward-looking statements include: trade regulations, export controls, trade disputes, and other geopolitical tensions may inhibit our ability to sell our products; our understanding of newly announced trade restrictions and their impact on our business may change over time; business, political and/or regulatory conditions in the consumer electronics industry, the semiconductor industry and the overall economy may deteriorate or change; the actions of our customers and competitors may be inconsistent with our expectations; supply chain cost increases and other inflationary pressures have impacted and may continue to impact our profitability; supply chain disruptions or manufacturing capacity constraints may limit our ability to manufacture and sell our products; and natural and human-caused disasters, disease outbreaks, war, terrorism, political or governmental unrest or instability, or other events beyond our control may impact our operations and revenue in affected areas; as well as the other risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission, including specifically the Risk Factors described in our annual report on Form 10-K for the fiscal year ended June 30, 2024 and quarterly report on Form 10-Q for the quarter ended September 29, 2024 . These uncertainties and changes could materially affect the forward-looking statements and cause actual results to vary from expectations in a material way. The Company undertakes no obligation to update the information or statements made in this press release. Company Contacts: Ram Ganesh Investor Relations (510) 572-1615 Email: investor.relations@lamresearch.com Source: Lam Research Corporation### View original content to download multimedia: https://www.prnewswire.com/news-releases/lam-research-corporation-comments-on-newly-announced-export-regulations-302320046.html SOURCE Lam Research Corporation
Kevin O'Connell highlights key trait that set Justin Jefferson and Jordan Addison apart from the rest
David Coote will not appeal against the termination of his contract by referees’ body PGMOL, the PA news agency understands. Coote was sacked earlier this month after the emergence of a video in which he made derogatory remarks about Liverpool and their former manager Jurgen Klopp. Professional Game Match Officials Limited (PGMOL) said that a thorough investigation had concluded he was “in serious breach of the provisions of his employment contract, with his position deemed untenable”. “Supporting David Coote continues to be important to us and we remain committed to his welfare,” PGMOL’s statement on December 9 added. Coote had the right to appeal against the decision but PA understands the Nottinghamshire referee has decided not to. The video which triggered PGMOL’s investigation into Coote’s conduct first came to public attention on November 11. In it, Coote is asked for his views on a Liverpool match where he has just been fourth official, and describes them as “s***”. He then describes Klopp as a “c***”, and, asked why he felt that way, Coote says the German had “a right pop at me when I reffed them against Burnley in lockdown” and had accused him of lying. “I have got no interest in speaking to someone who’s f****** arrogant, so I do my best not to speak to him,” Coote said. Later in the video, Coote again refers to Klopp, this time as a “German c***”. The Football Association opened its own investigation into that video, understood to be centred on that last comment and whether Coote’s reference to Klopp’s nationality constituted an aggravated breach of its misconduct rules. The investigation by PGMOL which led to Coote’s contract being terminated is also understood to have looked at another video which appeared to show Coote snorting a white powder, purportedly during Euro 2024 where he was one of the assistant VARs for the tournament. European football’s governing body UEFA also appointed an ethics investigator to look into the matter. We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate.
The Plasma Fractionation Market: Trends, Size, Share, Growth, and Demand Outlook to 2031 12-09-2024 09:26 PM CET | Health & Medicine Press release from: Data Bridge Market Research (DBMR) Plasma Fractionation Market The plasma fractionation market has emerged as a cornerstone of the healthcare industry, driven by its critical applications in treating life-threatening conditions such as immune deficiencies, hemophilia, and autoimmune disorders. Plasma fractionation is the process of separating plasma proteins into their individual components to create therapeutic products. As healthcare systems worldwide prioritize advanced treatment solutions, the demand for plasma-derived therapies has experienced a significant surge. This article delves into the key aspects of the plasma fractionation market, including its size, trends, growth prospects, and demand outlook through 2031. Access Full 350 Pages PDF Report @ https://www.databridgemarketresearch.com/reports/global-plasma-fractionational-market Plasma fractionation is a biotechnological process that separates blood plasma into its protein constituents, such as albumin, immunoglobulins, and clotting factors. These proteins are essential for managing a range of health conditions, including chronic illnesses and emergency situations. The growing prevalence of diseases requiring plasma-derived therapies, coupled with advancements in medical technology, has propelled the plasma fractionation market to the forefront of the pharmaceutical and biopharmaceutical industries. With a rising global population and aging demographics, the demand for plasma-derived products continues to climb. Governments, healthcare providers, and pharmaceutical companies are increasingly investing in plasma fractionation to address the healthcare challenges of modern society. Trends in the Plasma Fractionation Market The plasma fractionation market is shaped by several dynamic trends: Increased Focus on Rare Diseases Plasma-derived therapies play a critical role in treating rare and orphan diseases, such as primary immunodeficiency disorders and hereditary angioedema. Governments and healthcare organizations worldwide are placing greater emphasis on addressing these conditions, leading to increased investment in plasma fractionation. Advancements in Fractionation Technology Technological innovations in fractionation processes, including chromatography and nanofiltration, are improving the efficiency, safety, and yield of plasma-derived products. These advancements are driving the growth of the market by enabling the production of high-purity products. Rising Healthcare Expenditure As healthcare spending continues to rise globally, there is a greater focus on quality treatments and accessibility. Plasma-derived products, being integral to managing several critical health conditions, are seeing increased demand. Shift Toward Self-Sufficiency Many countries are aiming to reduce their reliance on imported plasma-derived products by investing in domestic plasma collection and fractionation facilities. This trend is likely to spur regional market growth. Increasing Public Awareness Public awareness campaigns highlighting the importance of plasma donation and its life-saving applications are driving an uptick in plasma collection rates, which in turn supports market expansion. Market Size and Share Data Bridge Market Research analyses that the global plasma fractionation market, which was USD 29,259.96 million in 2023, is expected to reach USD 48,425.11 million by 2031, at a CAGR of 6.5% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. Key players in the market hold a considerable share due to their extensive production capabilities and established distribution networks. Some of the leading companies include CSL Behring, Grifols, Octapharma, and Takeda. Together, these firms account for a significant portion of the market revenue, driven by their focus on innovation, product development, and strategic partnerships. Growth Drivers Rising Prevalence of Chronic Diseases Chronic diseases, including autoimmune disorders and neurological conditions, are on the rise globally. Plasma-derived therapies, such as intravenous immunoglobulins (IVIG) and clotting factor concentrates, are essential in managing these conditions. This has led to sustained growth in the plasma fractionation market. Aging Population With a growing aging population worldwide, the prevalence of age-related diseases such as Alzheimer's and cardiovascular disorders is increasing. These conditions often require plasma-derived treatments, fueling market demand. Expanding Plasma Collection Infrastructure Governments and private organizations are investing heavily in plasma collection infrastructure to meet rising demand. The expansion of collection centers is enhancing the availability of raw plasma, thereby supporting market growth. Regulatory Support Regulatory authorities, including the FDA and EMA, are providing favorable frameworks to streamline the approval and production processes for plasma-derived products. This has enabled faster market entry for new therapies. Emergence of Emerging Markets Developing economies in Asia-Pacific, Latin America, and the Middle East are witnessing increased investment in healthcare infrastructure. The rising awareness and availability of plasma-derived products in these regions present lucrative growth opportunities for the market. Demand Outlook to 2031 The demand for plasma-derived products is expected to witness substantial growth through 2031, driven by several factors: Global Healthcare Burden: Increasing prevalence of immunodeficiencies, bleeding disorders, and other chronic conditions is expected to boost demand. Regional Market Growth: North America and Europe will likely maintain their dominance due to established healthcare infrastructure and high awareness levels. However, Asia-Pacific is projected to grow at the fastest rate, thanks to improved healthcare access and increased plasma donation rates. Emerging Applications: Beyond traditional applications, plasma-derived products are finding use in treating emerging conditions, such as COVID-19 complications and other viral infections. Technological Innovations: The introduction of next-generation plasma-derived products, such as recombinant alternatives, will further enhance market prospects. Browse Trending Reports: https://aimarketresearch2024.blogspot.com/2024/12/fiber-cement-board-market-size-share.html https://aimarketresearch2024.blogspot.com/2024/12/plasma-fractionation-market-size-share.html https://aimarketresearch2024.blogspot.com/2024/12/non-cardioselective-beta-blockers.html https://aimarketresearch2024.blogspot.com/2024/12/maintenance-repair-and-operations_10.html Conclusion The plasma fractionation market is poised for sustained growth in the coming years, driven by a confluence of factors including rising healthcare needs, technological advancements, and expanding access in emerging markets. With its critical role in addressing life-threatening conditions and improving patient outcomes, plasma fractionation continues to be a priority for healthcare systems worldwide. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email: corporatesales@databridgemarketresearch.com" This release was published on openPR.Inside RTE Dancing With The Stars’ Kayleigh Trappe’s private life – from family & career to six stone weight lossNew Brexit deal is in your best interests, Reeves tells EU
SUBARU ANNOUNCES PRICING ON 2025 FORESTER WILDERNESSThis holiday season, be thankful for the taxpayer protections we have in California